GlassScriptPhysician profile
Raymond W Lee
NPI 1053317818
$21,100.72
in general payments reported to CMS, 2019-2025
62 companies · $3,817 in 2025
The $3,817 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,032 · 2020: $2,041 · 2021: $1,696 · 2022: $2,332 · 2023: $2,325 · 2024: $2,858 · 2025: $3,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,378 · Education: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,377.68 |
| Education | $622.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,538.82 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Rigel Pharmaceuticals, INC. | $1,513.12 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Janssen Biotech, INC. | $1,309.51 | 2019-2025 | Darzalex, Talvey, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $1,096.25 | 2019-2025 | Opdivo, Eliquis |
| Pfizer INC. | $1,003.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $943.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $800.64 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $784.76 | 2020-2025 | Xtandi, Vyloy, Padcev |
| Lilly USA, LLC | $615.79 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Seagen INC. | $602.02 | 2019-2023 | Adcetris, Tivdak |
| Glaxosmithkline, LLC. | $460.08 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $321.12 | 2020-2025 | Fruzaqla, Advate |
| Celgene Corporation | $295.15 | 2019-2025 | Reblozyl, Pomalyst |
| Sobi, INC | $251.44 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.98 | 2019-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $234.23 | 2021-2025 | |
| Beone Medicines USA, INC. | $223.37 | 2025 | Tevimbra, Brukinsa |
| Abbvie INC. | $212.96 | 2023-2025 | |
| Coherus Oncology, INC. | $211.71 | 2024-2025 | Loqtorzi |
| Daiichi Sankyo INC. | $208.80 | 2023-2025 | Enhertu, Datroway |
| Progenics Pharmaceuticals, INC. | $203.90 | 2023-2025 | Pylarify |
| Array Biopharma INC | $179.42 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $171.17 | 2021-2025 | Kyprolis, Vectibix, Nplate |
| Kite Pharma, INC. | $154.45 | 2020-2025 | Yescarta |
| Pharmaessentia USA Corporation | $145.06 | 2024-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $136.87 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2019 | |
| Novocure INC. | $115.40 | 2025 | Optune Lua (Novottf-200t) |
| Emd Serono, INC. | $109.26 | 2019-2024 | Bavencio |
| Dova Pharmaceuticals | $101.74 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $100.34 | 2023-2025 | Qinlock, Romvimza |
| Amarin Pharma, INC. | $100.00 | 2019 | |
| Puma Biotechnology, INC. | $98.28 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $97.48 | 2024 | Libtayo |
| Intuitive Surgical, INC. | $94.59 | 2023 | Da Vinci Surgical System |
| Foundation Medicine, INC. | $90.84 | 2019-2021 | |
| Blueprint Medicines Corporation | $86.89 | 2021-2025 | Ayvakit |
| Legend Biotech USA INC. | $74.66 | 2025 | Carvykti |
| Genentech USA, INC. | $73.68 | 2022-2023 | Perjeta, Phesgo, Tecentriq |
| Pharmacyclics LLC, An Abbvie Company | $71.06 | 2021-2023 | Imbruvica |
| Gilead Sciences, INC. | $68.72 | 2019-2025 | Trodelvy |
| Clovis Oncology, INC. | $67.02 | 2019-2022 | |
| Incyte Corporation | $65.48 | 2021-2022 | |
| Stemline Therapeutics INC. | $63.79 | 2024-2025 | Orserdu |
| Acrotech Biopharma INC. | $57.54 | 2021-2025 | Beleodaq |
| Genzyme Corporation | $54.36 | 2020-2025 | |
| Merz North America, INC. | $52.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.05 | 2023-2024 | Gilotrif |
| Tolmar Pharmaceuticals, INC. | $42.00 | 2021 | |
| Adc Therapeutics America, INC. | $38.81 | 2022 | |
| Jazz Pharmaceuticals INC. | $38.01 | 2019 | |
| Taiho Oncology, INC. | $36.01 | 2024 | |
| Agios Pharmaceuticals, INC. | $35.83 | 2025 | Pyrukynd |
| Elekta, INC. | $33.54 | 2023 | Elekta Unity |
| Sumitomo Pharma America, INC. | $32.93 | 2024 | Orgovyx |
| Genmab U.S., INC. | $27.73 | 2024 | Epkinly |
| Cti Biopharma Corp. | $26.77 | 2023 | Vonjo |
| Novo Nordisk INC | $25.27 | 2025 | Wegovy |
| Tempus Ai, INC | $25.14 | 2024 | |
| Beigene USA, INC. | $22.89 | 2024 | Tevimbra |
| Morphosys, US INC. | $20.51 | 2022 | |
| Vyera Pharmaceuticals, LLC | $15.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.